LVenture Group SpA is a holding company listed on the Italian Stock Exchange (MTA), operating in the field of Venture Capital. It owns the Startup Accelerator LUISS EnLabs, born from a joint venture with Luiss University, which has grown into a point of reference in Italian innovation ecosystem. We provide a 9,000 sqm Hub in Rome’s Termini Station, in addition to a dedicated office space in Milan, at the Milan LUISS Hub. Today our investment portfolio includes 90+ startups, characterized by high digital innovation and scalability. Our business model is based mainly on capital gains from the exits of our startups.  #investnow

LVenture Group

IAG is an angel investor network that offers access to its affiliates to early-stage venture opportunities.  Its members to date have deployed over 22 million Euros to support 41 startups in the series seed/series A stage in many verticals, among which: Medtech, SAAS, e-commerce, Fintech, and high tech at large.  Every investment opportunity at IAG is vetted by a professional team together with expert members of the group.  Once invested, the company receives the support of up to two Investment champions, who bring their expertise to the table and help them succeed.

Italian Angels for Growth

Lumen Ventures is a venture capital firm that focuses on early-stage investments.

Lumen Ventures

Each of the 20 companies accepted into the SkyDeck full cohort will receive investment of $200,000 from the Berkeley SkyDeck Fund. Each of the 10 startups accepted into SkyDeck Europe will receive investment of €145,000 from our dedicated European Fund. Berkeley SkyDeck is UC Berkeley’s global startup accelerator. Named in Forbes as a top five U.S. university accelerator, SkyDeck combines hands-on mentorship with the vast resources of its research university. Participating startups have access to SkyDeck’s 480 advisors, 50 industry partners, and a network of more than 510,000 UC Berkeley alumni.

SkyDeck Berkeley

GCM Group

a|impact invests in the prevailing form of equity or quasi-equity, focusing our operations mainly on companies.

a|impact

Padda Health is a Venture capital firm investing in healthcare startups.

Padda Health

Finalca

Scientifica Venture Capital offers private equity and venture capital investment services for Italy based startups and firms.

Scientifica Venture Capital

Lazio Innova is a venture capital firm with its headquarters in Rome in Italy. The firm provides services in areas such as credit support and guarantees, interventions in risk capital, internationalization services, promotion of business networks and services for the creation and enterprise development.

Lazio Innova

GenomeUp

Rome-based healthtech startup that offers an ecosystem of AI-powered solutions for genetic analysis and clinical decision support for diseases. GenomeUp's mission is to be a global reference platform to support clinical decision-making for hospitals, laboratories, research centers, and pharmaceuticals to accelerate diagnosis times, improve patient care and provide knowledge for health prevention, all in less than 24h. Based on these assumptions, the founders decided to evolve the startup and transform it into a Italian Benefit Corporation following the purpose of common benefit by acting responsibly, sustainably and transparently towards stakeholders, people, communities, the territory and the environment.

GenomeUp is an Italian healthtech company based in Rome that provides an AI-powered software platform called JuliaOmix for genetic analysis and clinical decision support. Launched in 2017, the company operates in the niche sector of accurate diagnosis and treatment planning for individuals suffering from rare genetic diseases. JuliaOmix enables physicians and genetic biologists to collaborate by collecting patients' health data, including symptoms, treatments, phenotypes, and omics data (whole genome, exome, and microbiome). It then provides AI-based clinical interpretations and reports on genomic variants. GenomeUp's long-term goal is to establish JuliaOmix as a reference platform that accelerates diagnosis times, improves patient care, and enhances understanding of genetic diseases. In February 2022, the company raised USD 1.2 million in a seed funding round to bolster its team and continue developing the platform. GenomeUp is certified for various ISO standards by Bureau Veritas and is qualified as a SaaS service provider by the Agenzia per l'Italia Digitale.

Italy’s AI-powered rare genetic disease detector GenomeUp raises $1.2 million

83 Top Health Care Startups and Companies in Italy (2021)

Juliaomix

Diagnostics made simple

Automation in clinical diagnostics to improve speed and accuracy in patient diagnosis and treatment.

Clinical Decision Support Systems

GenomeUp is an Italian healthtech company based in Rome that provides an AI-powered software platform called JuliaOmix for genetic analysis and clinical decision support. Launched in 2017, the company operates in the niche sector of accurate diagnosis and treatment planning for individuals suffering from rare genetic diseases. JuliaOmix enables physicians and genetic biologists to collaborate by collecting patients' health data, including symptoms, treatments, phenotypes, and omics data (whole genome, exome, and microbiome). It then provides AI-based clinical interpretations and reports on genomic variants. GenomeUp's long-term goal is to establish JuliaOmix as a reference platform that accelerates diagnosis times, improves patient care, and enhances understanding of genetic diseases. In February 2022, the company raised USD 1.2 million in a seed funding round to bolster its team and continue developing the platform. GenomeUp is certified for various ISO standards by Bureau Veritas and is qualified as a SaaS service provider by the Agenzia per l'Italia Digitale.

<div>
 
 Clover Health is a healthcare company focused on serving Medicare Advantage members. The company leverages its proprietary software platform, the Clover Assistant, to aggregate and analyze patient data from across the healthcare ecosystem. This data-driven approach aims to support clinical decision-making and improve health outcomes for seniors.
 
 
 
 
 Clover Health operates in two segments: Insurance and Non-Insurance. Through its Insurance segment, the company provides PPO and HMO plans to Medicare Advantage members across several states. As of March 2022, Clover Health had approximately 257,000 lives under its management, a significant increase from around 66,000 lives in the first quarter of 2021.
 
 
 
 
 The Clover Assistant is a key component of Clover Health's strategy. This software platform is designed to provide physicians with relevant patient information to facilitate coordinated care. The company reported that in 2021, its Insurance members whose primary care providers (PCPs) utilized the Clover Assistant had a significantly lower medical care ratio (MCR) compared to members whose PCPs did not use the platform.
 
 
 
 
 In its Non-Insurance segment, Clover Health participates in the Centers for Medicare &amp; Medicaid Services' (CMS) Direct Contracting model, which will transition to the ACO Reach model in 2023. This segment involves aligning with Original Medicare beneficiaries through provider attribution or voluntary alignment.
 
 
 
 
 For the full year 2022, Clover Health expected total revenues to range from USD 3.0 billion to USD 3.4 billion, including projected Insurance revenue of USD 1.0 billion to USD 1.1 billion and Non-Insurance revenue of USD 2.0 billion to USD 2.3 billion. The company also anticipated an improvement in its Insurance MCR, falling within the range of 95% to 99%, driven by operational efficiencies, increased risk scores, and lower Covid-19 costs.
 
 
 
</div>

Clover Health

Digital Diagnostics is a healthcare technology company that develops artificial intelligence (AI) systems for disease diagnosis by analyzing medical images. The company's flagship product, LumineticsCore (formerly known as IDx-DR), is an FDA-cleared autonomous AI system designed to detect diabetic retinopathy and diabetic macular edema during a patient encounter without needing a physician to interpret the images. LumineticsCore increases patient access to care by providing diagnostic results at the point-of-care, eliminating the need for an additional appointment for most patients. This enables healthcare providers to close the gap in eye exams for diabetes care by offering a specialty-level diagnostic exam where the patient receives care.
Digital Diagnostics has also developed DermSpot, an AI system for detecting certain types of skin cancer, which is currently for investigational use only. The company aims to create AI diagnostic solutions that improve patient outcomes, increase healthcare productivity, and enhance accessibility and affordability of care. In April 2023, Digital Diagnostics expanded LumineticsCore to Labcorp patient service centers in Alabama.
Key customers and partnerships
In 2022, Digital Diagnostics signed a long-term strategic partnership with Baxter International to help front-line care providers deliver high-quality care and improve outcomes. The company also partnered with ArchWell Health to bring LumineticsCore to ArchWell Health centers across the US.
Additionally, Digital Diagnostics entered into a memorandum of understanding with the Kingdom of Saudi Arabia's Ministry of Investment in 2022 for international expansion.

Digital Diagnostics

Lunit is a leading provider of AI-powered solutions for cancer diagnostics and therapeutics. The company's flagship product, Lunit INSIGHT, is a suite of AI solutions for radiology that has been approved for commercial use in Europe and the UK through the MDR CE and UKCA certifications obtained in November 2022. The suite includes Lunit INSIGHT CXR for chest X-ray analysis and Lunit INSIGHT MMG for mammography analysis. Lunit INSIGHT CXR can detect 10 chest abnormalities, including pulmonary nodules and pneumothorax, with 97-99% accuracy, while Lunit INSIGHT MMG detects breast cancer with 96% accuracy.
After receiving FDA clearance, Lunit's solutions are clinically used in approximately 3,000 hospitals and medical institutions across 40 countries as of March 2024. In April 2024, a study published in European Radiology demonstrated that Lunit INSIGHT MMG could potentially reduce radiologists' workload by nearly 70% and boost cancer detection accuracy by 30.5%, showcasing its ability to enhance operational efficiency and improve patient outcomes.
In May 2024, Lunit completed the acquisition of Volpara Health Technologies, a New Zealand-based company offering software for early cancer detection, for USD 193 million. The acquisition aimed to strengthen Lunit's presence in the US market and leverage Volpara's robust repository of over 100 million medical images to develop innovative solutions for cancer diagnostics.
Key customers and partnerships
Lunit has established strategic partnerships to expand its reach and integrate its AI solutions into healthcare systems worldwide. In March 2024, the company signed supply contracts with Chung Shan Medical University in Taiwan and Gleneagles Hospital in Singapore to provide Lunit INSIGHT CXR and Lunit INSIGHT MMG, respectively. These collaborations aimed to enhance lung and breast cancer detection in the East and Southeast Asian regions.
In November 2023, Lunit partnered with NTT DATA Singapore to introduce Lunit INSIGHT CXR to Singapore's public healthcare system through the AimSG platform, a national medical imaging AI initiative. The solution was piloted at Singapore General Hospital and Changi General Hospital, two major public hospitals, to enhance the efficiency of chest screening and provide innovative medical services with improved accuracy.
Lunit has also collaborated with leading healthcare technology companies, such as GE healthcare, Fujifilm, Philips, and Guardant Health, to deploy its AI products and leverage their distribution networks.

Lunit

Lumeon is a digital health company that provides a cloud-based Care Orchestration platform designed to automate and streamline the care coordination process for healthcare providers. The platform leverages real-time, bi-directional data integration and applies dynamic clinical intelligence to ensure that patients receive the right care at the right time, every time.
Lumeon's Care Orchestration platform acts as a "care traffic control" center, synchronizing disparate data across the care continuum, orchestrating and automating care pathway activities, and delivering relevant information to care teams and patients. By automating routine tasks and workflows, the platform enables care teams to focus on providing direct patient care, working at the top of their licenses.
The platform integrates with electronic health records (EHRs) and other systems, creating a real-time synthetic patient record to inform care decisions. It visualizes care plans, virtualizes monitoring, and automates routine tasks, ultimately reducing manual intervention and associated costs for providers. The platform can be deployed enterprise-wide and applied across various use cases within a healthcare system.
Key features of Lumeon's Care Orchestration platform include real-time bi-directional data integration with EHRs and other systems, automation of care orchestration tasks and workflows, and the ability to present information through multiple modalities, including within EHRs, native interfaces, web portals, and mobile apps.
Lumeon's platform has been deployed by leading healthcare providers in the US and Europe across more than 2,000 care locations, delivering measurable results in as little as 90 days.

Lumeon

Proscia is a software company that develops digital and computational pathology solutions. Its flagship product, Concentriq, is an enterprise pathology platform that serves as a hub for digital pathology data and AI applications. Concentriq bridges the gap between anatomic pathology laboratories and life sciences organizations, enabling real-world pathology data to fuel innovation that enhances patient care.
The platform delivers an open environment to run a range of AI applications, including Proscia's proprietary algorithms and those developed by partners or customers. One such AI solution is DermAI, a dermatopathology module launched in June 2019 to assist laboratories in tasks like case prioritization, automated quality assurance, and enhanced technical component reporting.
In February 2024, Proscia received 510(k) clearance from the FDA for its Concentriq AP-Dx solution for primary diagnosis in clinical settings. This comprehensive diagnostic software streamlines collaboration and helps drive confidence and efficiency gains. As of December 2023, over 10,000 pathologists and scientists, including those at leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies, used Proscia's solutions.
Furthermore, in December 2023, CellNetix Pathology & Laboratories announced a collaboration with Proscia to digitize a portion of its 1 million glass slides per year and adopt AI-powered digital pathology workflows.

Proscia

Software that provides a list of possible diseases based on data collected from patients. Platforms are only used for initial assessments.

Platforms and software that generates alerts based on patient treatment and current status.

Platforms and software that monitor and track treatment plans of patients, identifies possible treatment issues, and suggests alternative treatment options.

Workflow management software that helps clinicians track and follow procedure for operations.

Companies that use GenAI as a core part of their product offering for Clinical Decision Support Systems

Uses digital mediums to generate actionable insights from health data

Clinical Decision Support System providers incorporate GenAI to enhance their systems

In most cases, CDSSs are provided to healthcare providers

Uses IoT to connect databases with medical devices for decision support

Uses AI/ML to output decisions/recommended actions based on databases of medical records

GenomeUp

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless